An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Latest Information Update: 13 Apr 2017
Price :
$35 *
At a glance
- Drugs Sapanisertib (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 13 Apr 2017 New trial record